GlassScriptPhysician profile
David S Rogers
NPI 1528045978
$54,286.66
in general payments reported to CMS, 2019-2025
46 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $29K · 2021: $8,104 · 2022: $1,595 · 2023: $960 · 2024: $994 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $9,350 · Food and Beverage: $3,514 · Travel and Lodging: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $9,350.00 |
| Food and Beverage | $3,513.65 |
| Travel and Lodging | $922.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28,971.96 | 2020-2021 | |
| Axsome Therapeutics, INC. | $11,153.45 | 2024-2025 | Symbravo, Sunosi |
| Abbvie INC. | $3,526.02 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Biodelivery Sciences International, INC. | $3,146.87 | 2019-2021 | |
| Forte Bio-Pharma LLC | $2,323.37 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Amgen INC. | $572.42 | 2019-2023 | Aimovig |
| Lundbeck LLC | $554.50 | 2020-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $453.59 | 2019-2024 | Qelbree |
| Jazz Pharmaceuticals INC. | $427.24 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $424.28 | 2022-2023 | Austedo, Ajovy, Austedo Xr |
| Lilly USA, LLC | $417.02 | 2019-2025 | Kisunla, Amyvid |
| Collegium Pharmaceutical, INC. | $313.13 | 2019-2023 | Belbuca |
| Pfizer INC. | $241.52 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $213.93 | 2020-2022 | |
| Upsher-Smith Laboratories LLC | $191.07 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.